戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              NF-IL6 is an important transcriptional regulator of gene
2                                              NF-IL6 is first detectable after 3 h of infection and co
3                                              NF-IL6 production could not be induced by UV-inactivated
4                                              NF-IL6 utilizes two distinct regions to bind to the hypo
5                                              NF-IL6-mediated transcriptional activation is enhanced 3
6 taining cytokine and hypoxia-sensitive AP-1, NF-IL6, and NF-kappaB sites, was insufficient for induct
7 ctors activating protein-1, serum protein-1, NF-IL6, or cyclic adenosine monophosphate responsive ele
8 (NFkappaB) and nuclear factor interleukin 6 (NF-IL6 or C/EBP) activation and bacteremia, inflammatory
9 on with the nuclear factor of interleukin 6 (NF-IL6, also known as CCAAT enhancer binding protein (C/
10  also known as nuclear factor-interleukin-6 (NF-IL6), is a transcription factor that plays an importa
11 ncer action of nuclear factor-interleukin-6 (NF-IL6).
12 ve human transcription factors: NFAT1, ALL1, NF-IL6, ESX, and HSF-1.
13 re, RARs and RXRs do not bind in vitro to an NF-IL6 binding site.
14 g of NF-kappaB; however, binding of AP-1 and NF-IL6 was inhibited.
15 g sites including AP-2, Sp1, CRE, PEA-3, and NF-IL6.
16 elements, IRF-1 located at -730 to -719, and NF-IL6 at -520 to -512, were also studied by deletion an
17 nt- binding protein, ICER IIgamma, ATF3, and NF-IL6 in hepatocytes.
18 tion via the cyclic AMP response element and NF-IL6 sites of the COX-2 promoter.
19                 Interaction between HSF1 and NF-IL6 could thus be an important mechanism in HSF1 regu
20 tors ATF3, gadd153/Chop10, ICER IIgamma, and NF-IL6.
21                            The NF-kappaB and NF-IL6 elements have previously been shown to play an im
22 on sites for factors including NF-kappaB and NF-IL6 involved in responses to various cytokine and hor
23  for the transcription factors NF-kappaB and NF-IL6.
24 tein (AP)-1, nuclear factor (NF)-kappaB, and NF-IL6 in respiratory syncytial virus (RSV)-induced inte
25 uced in activated monocytes/macrophages, and NF-IL6 is the only CCAAT/enhancer-binding protein (C/EBP
26 tivation of hepatic and splenic NFkappaB and NF-IL6 positively correlates with tissue cytokine mRNA e
27 ar factor (NF)-IL6/CREB, NFB1, NFkappaB, and NF-IL6], consistent with the activation of an upstream s
28 ation of transcriptional factors NF-kappa B, NF-IL6, cyclic adenosine monophosphate responsive elemen
29 e human homolog of chicken NF-M, C/EBP-beta (NF-IL6).
30 n a concentration-dependent decrease in both NF-IL6/CREB binding to the IL-1beta promoter and IL-1bet
31 ffect COX-2 promoter activity, mutating both NF-IL6 sites substantially inhibits COX-2 promoter activ
32  NF-IL6 and to the synergistic activation by NF-IL6 and Spi.1.
33  inhibitory to transcriptional activation by NF-IL6 and to the synergistic activation by NF-IL6 and S
34 uences in producing HIV-1 gene activation by NF-IL6.
35 ces in vitro and promoter transactivation by NF-IL6 in cells.
36                              In HepG2 cells, NF-IL6 elicits a relatively low level of gene activation
37                  Additionally, TAD-deficient NF-IL6 functions as a dominant negative for Spi-1-mediat
38  promoter (-59/+12) in the absence of direct NF-IL6 binding to DNA.
39 B and CCAAT/enhancer-binding protein (C/EBP; NF-IL6) sites in the IL-6 promoter are important for coo
40 In addition, the cytokine response elements (NF-IL6 binding sites) in opioid receptor genes are not f
41 ontain potential cytokine response elements (NF-IL6 binding sites).
42 t in the absence of NF-IL6 binding elements, NF-IL6 can elicit LTR-mediated gene expression in cotran
43 urkat) and hepatoma cells (HepG2), exogenous NF-IL6 can activate HIV-1 gene expression even in the ab
44 Spi-1 (also called PU.1) and the bZIP factor NF-IL6 (also called C/EBPbeta) have been shown to be inv
45 nds to the basic zipper transcription factor NF-IL6 required for activation of c-fms and IL-1beta.
46 f the immune regulatory transcription factor NF-IL6.
47 aptamers" targeting the transcription factor NF-IL6.
48 on by cytokine-induced transcription factor, NF-IL6, using a number of immune cell lines which respon
49 o interact with other transcription factors, NF-IL6 is involved in transcriptional regulation of a wi
50 ng was done to investigate the mechanism for NF-IL6 production.
51 ing the requirement of viral replication for NF-IL6 synthesis.
52 hancer binding protein recognition sites for NF-IL6.
53                                      Hepatic NF-IL6 activation was observed at 3, 4, and 6 hours afte
54                                     The HSF1/NF-IL6 interaction involves a sequence of HSF1 containin
55 of the transcription start site of the human NF-IL6 gene to evaluate the predictions of two computati
56                   This manuscript identifies NF-IL6 as another transcription factor, in addition to A
57 fect of RSV infection on nuclear factor-IL6 (NF-IL6) expression, a human basic domain-leucine zipper-
58 or-kappa B (NF-kappa B), nuclear factor-IL6 (NF-IL6), cyclic adenosine monophosphate responsive eleme
59 tightly to the nuclear factor for human IL6 (NF-IL6), a basic leucine zipper transcription factor inv
60 nding sites show a virus-induced increase in NF-IL6-dependent transcription.
61  of RAR and RXR is obligatory for inhibiting NF-IL6 activity.
62 n the abundance or size of the single 1.8-kb NF-IL6 mRNA.
63  genes driven by either wild-type or mutated NF-IL6 binding sites show a virus-induced increase in NF
64     In these experiments, isolated NFkappaB, NF-IL6, and CRE promoter sites were less effective than
65 r-luciferase construct showed that NFkappaB, NF-IL6, and CRE promoter sites mediate gene transcriptio
66 tional regulatory factor NF-kappa B (but not NF-IL6, cyclic adenosine monophosphate responsive elemen
67 ences retain a significant fraction (42%) of NF-IL6 responsiveness in the absence of upstream regulat
68  HepG2 cells, we find that in the absence of NF-IL6 binding elements, NF-IL6 can elicit LTR-mediated
69 ction by antagonizing the enhancer action of NF-IL6, a basic domain leucine zipper transcription fact
70  mutant RB enhanced both binding activity of NF-IL6 to its cognate DNA sequences in vitro and promote
71                      Furthermore, binding of NF-IL6 (C/EBPbeta) and c-Jun to the SPRR1A promoter was
72 cible mechanism for translational control of NF-IL6 synthesis and identify this transcription factor
73 ponsible, at least in part, for induction of NF-IL6 mRNA following activation of U937 promonocytic ce
74                          The interdiction of NF-IL6-dependent signal transduction pathway by RARs may
75 549) synthesize a single 45.7-kDa isoform of NF-IL6 rapidly and in a time-dependent manner.
76  that synthetic retinoids with properties of NF-IL6 antagonism but lacking transactivation capabiliti
77 nd regulatory domains and the bZip region of NF-IL6.
78 enhancer binding protein beta (C/EBPbeta, or NF-IL6) is expressed in macrophages, where it participat
79  be the preferred transcription factor (over NF-IL6) for cooperative interaction with NF-kappaB in RS
80                             There was robust NF-IL6 protein synthesis within RSV-infected (24 h) cell
81 the highest specificity in binding to target NF-IL6.
82 lix (wHTH) DNA binding domains, arguing that NF-IL6 vigorously activates the il1b core promoter via p
83 ive synthetic retinoids, we demonstrate that NF-IL6 antagonism and transactivation are separable func
84                            We also show that NF-IL6 acts as a transcriptional enhancer of MRP-8, and
85                                          The NF-IL6 antagonism function of RAR is a complex of the co
86                                          The NF-IL6 site is also important for COX-2 transcription in
87 lso found that an ETS site (-75/-72) and the NF-IL6 site were responsible for COX-2 activity induced
88 stration of in vitro interaction between the NF-IL6 bZIP and Spi-1 winged helix-turn-helix (wHTH) DNA
89                             Furthermore, the NF-IL6 transactivation domain (TAD) is functionally indi
90                                 However, the NF-IL6 gene is expressed in a variety of nonmyeloid cell
91 with increased C/EBP binding activity in the NF-IL6 site of EP4 promoter region and C/EBPbeta protein
92 romoters, showed that the Spi-1, but not the NF-IL6, binding site is absolutely required for function
93 ibutes independently to transcription of the NF-IL6 gene in U937 cells.
94  We show that increased transcription of the NF-IL6 gene is responsible, at least in part, for induct
95 fied a 104-bp minimal promoter region of the NF-IL6 gene that is sufficient for basal and activation-
96                              Mutation of the NF-IL6 site had minimal effect in the presence of intact
97 romoter mapping experiments suggest that the NF-IL6 site in the COX-2 promoter is important for media
98 ition blocks IL-1beta-induced binding to the NF-IL6 element of the COX-2 promoter and inhibits transc
99 ot only the binding activity of C/EBP to the NF-IL6 site in the EP4 promoter, which was prevented by
100                                    Using the NF-IL6 transcription factor we show that the assay can d
101                     In addition, even though NF-IL6 induces a relatively low gene activity from the b
102                                        Thus, NF-IL6 is a potential therapeutic target for the treatme
103  addition, HSF2 is not capable of binding to NF-IL6.
104 r the first time that HSF1 binds directly to NF-IL6 in vivo and antagonizes its activity.
105 ed for the responsiveness of Sp1 elements to NF-IL6 in this cellular background.
106 ion from the basal LTR elements; response to NF-IL6 is restored with either the Sp1 binding sequences
107                    Although mutating the two NF-IL6 sites individually did not affect COX-2 promoter
108 umor antigen (T antigen)-binding domain with NF-IL6, a member of the CAAT/enhancer-binding protein (C

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top